

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_80783
Title of the Manuscript:	Fibroblast growth factor 23 (FGF23) is an early specific marker in the diagnosis and staging of chronic kidney disease (CKD) in human
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ol style="list-style-type: none">1) Please explain why the authors excluded diabetic patients . In my clinical practice round about 50% of my patients are diabetic. Is FGF23 also a specific marker for staging CKD in diabetics ?2) Why the authors do not mention the KDIGO guidelines for the classification of CKD, in their study ?3) Is it possible to have the demographic data of the patients (age , gender, BMI, aetiology of CKD, etc.)?4) Is there an association between FGF23 and parameters mentioned in (3) (age , gender, BMI, aetiology of CKD, etc.)?	
Minor REVISION comments		
Optional/General comments		

Review Form 1.6

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Maria Mesquita
Department, University & Country	Université Libre De Bruxelles (ULB), Belgium